Obesity medications: Weight loss in clinical practice probably lower than in studies
In clinical practice, average weight reductions in obese patients treated with semaglutide and tirzepatide appear to be lower than in clinical trials. According to a US cohort study, this is primarily due to treatment discontinuations, which in the US are primarily due to high out-of-pocket costs and drug shortages. Another reason was lower maintenance therapy dosages.
Arzte zeitung
